Eric C. Jeschke
127 IP cases indexed. Covers patent matters.
Cases Presided Over
127 cases indexed | Page 1 of 5
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson and Omachron settled all disputes over four patents, filing a joint motion that led the PTAB to terminate the inter partes reviews without a final written decision.
Imperative Care, Inc. v.INARI MEDICAL, INC.
The PTAB instituted an IPR on Inari Medical’s 11,697,012 B2 hemostasis valve patent after finding Imperative Care likely to prevail on at least one claim, based on anticipation and obviousness arguments over Schaffer, Hartley, Eller, and Garrison references.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson and Omachron settled their IPR dispute over U.S. Patent 7,776,120, leading the PTAB to terminate the proceeding before any merits were decided.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 B2 embolism‑treatment patent after finding Imperative Care likely to prevail on at least one claim, primarily on obviousness grounds involving hemostasis valve features.
Eunsung Global Corp. v.HydraFacial LLC et al.
Eunsung Global and HydraFacial settled their inter partes review disputes before the PTAB instituted a trial. The Board granted joint motions to terminate and to keep the settlement agreement confidential, ending the proceedings.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s likelihood of success on at least one claim. All nine claims are now under review.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s ’291 hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success. All 16 challenged claims are now under review.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted inter partes review on all 15 claims of Inari Medical’s embolism‑treatment patent after finding Imperative Care’s obviousness arguments sufficiently persuasive.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,012 patent covering hemostasis valves after finding Imperative Care’s petition shows a reasonable likelihood of success on at least one claim.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis valve patent are unpatentable. The Board’s claim construction of “filament” as a flexible element undermined the anticipation argument and found the obviousness combinations persuasive.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB denied Imperative Care's petition to institute an IPR against Inari Medical's embolism‑treatment patent, finding no reasonable likelihood of success on any of the 31 challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s hemostasis valve patent (U.S. Patent 11,697,012) on all nine claims after finding the challenger, Imperative Care, showed a reasonable likelihood of prevailing. The dispute centers on claim construction of “filament” and alleged anticipation/obviousness over prior‑art references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care’s petition to invalidate Inari Medical’s hemostasis valve patent was granted. The Board found a reasonable likelihood of success on anticipation and obviousness grounds and instituted review of all nine claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 B2 embolism‑treatment patent after finding Imperative Care likely to prevail on at least one claim. All 15 claims are now under review.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted inter partes review of Inari Medical’s 11,844,921 B2 hemostasis valve patent after finding Imperative Care has shown a reasonable likelihood of success on at least one claim. The dispute centers on whether the claimed “filament” must be flexible, with the Board presently favoring the patent owner’s interpretation.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
In an IPR, the PTAB held that all nine claims of Inari Medical’s hemostasis valve patent are unpatentable under §§102 and 103, finding the petitioner’s anticipation and obviousness arguments persuasive.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s likelihood of success sufficient. All nine claims are now under trial.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted institution of an IPR against Inari Medical’s 12,016,580 hemostasis valve patent, finding a reasonable likelihood that Imperative Care will prevail on at least one of the nine challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s hemostasis valve patent after Imperative Care showed a reasonable likelihood of success, focusing on the definition of “filament” and its flexibility versus prior art.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care successfully instituted an IPR against Inari Medical's 11,969,333 B2 patent covering intravascular clot removal. The Board found a reasonable likelihood of unpatentability based on obviousness over Laub, Garrison, and related references, and instituted review on all 36 challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success on at least one claim.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,974,910 patent after finding Imperative Care likely to succeed on at least one claim, focusing on obviousness over Garrison, Laub, and Aklog references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,844,921 B2 hemostasis valve patent after Imperative Care showed a reasonable likelihood of success on multiple claims. The dispute centers on the definition of “filament” and reliance on prior art Schaffer, Hartley, and Eller.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care secured an institution of inter partes review against Inari Medical’s hemostasis valve patent covering claims 1‑9. The Board found a reasonable likelihood of unpatentability based on anticipation and obviousness grounds involving Schaffer, Hartley, and Eller references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 patent covering intravascular embolism treatment devices after finding Imperative Care’s likelihood of success on at least one claim. The decision centers on claim constructions of the “filament” element and obviousness over multiple prior‑art references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an IPR on Inari Medical’s 11,697,012 patent covering hemostasis valves for aspiration catheters after finding a reasonable likelihood that Imperative Care will prevail on at least one of the nine challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care seeks to invalidate nine claims of Inari Medical’s 11,697,012 hemostasis valve patent. The PTAB instituted the IPR, finding a reasonable likelihood of unpatentability based on multiple prior‑art references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s embolism‑treatment patent after finding Imperative Care’s obviousness arguments sufficiently persuasive. All 36 challenged claims are now under review.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted inter partes review of Inari Medical’s 11,974,910 clot‑treatment patent after Imperative Care showed a reasonable likelihood of success on multiple obviousness grounds.
MPL Brands NV, Inc. v.BuzzBallz, LLC
The PTAB issued a final written decision finding all six claims of the '904 patent unpatentable. The Board determined that the claimed features were anticipated or obvious over prior art references (Kick, Ackermann, Kaminski, Hutchinson).
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.